Budde K, Fritsche L, Mai I, Bauer S, Smettan S, Waiser J, Hofmann T, Hauser I, Reinke P, Neumayer H H
Department of Internal Medicine-Nephrology, Universitätsklinikum Charité, Humboldt University, Berlin.
Int J Clin Pharmacol Ther. 1996 Nov;34(11):493-7.
Tacrolimus, a potent new immunosuppressive drug, was introduced for rescue therapy in 25 renal transplant recipients with ongoing rejection (n = 24) or severe cyclosporine toxicity (n = 1). A highly significant (p < 0.001) rise in serum creatinine from 138 +/- 14 (3 months before conversion) to 295 +/- 26 mumol/l preceded conversion to tacrolimus. Tacrolimus rescue therapy started 73 +/- 9 months after transplantation, the follow-up was 8 +/- 1 months. Outcome, pharmacokinetics, and side-effects were analyzed. Patient survival was 100% on tacrolimus therapy. Graft survival was 88% after 3 months, and 70% after 8 months. Serum creatinine remained stable during the observation period (Crea after 8 months: 271 +/- 26 mumol/l). Starting with an initial dose of 9.6 +/- 0.3 mg/day (0.14 +/- 0.01 mg/kg/day) we could reduce tacrolimus dose to 6.0 +/- 0.9 mg/day (0.09 +/- 0.02 mg/kg/day; p < 0.001) after 1 month. Tacrolimus trough levels were adjusted to a therapeutic window of 5-8 ng/ml. We had to perform 3.4 +/- 0.5 dose adjustments per patient mainly within the first month after conversion (70%). A high variability in interindividual tacrolimus dose was noted. Last cyclosporine dose was a good predictor of required tacrolimus dose after 1 month (r = 0.88; p < 0.001). Overall, 82 adverse events were noted, of which 29 (35%) were associated with high trough levels (> 10 ng/ml). In contrast, 3 patients with trough levels < 4 ng/ml had ongoing rejection. Blood pressure and routine laboratory data remained unchanged. Steroid dose could be tapered from 12 +/- 2 to 5 +/- 0.3 mg/day (p < 0.02). Gingival hyperplasia and hirsutism improved after conversion. We conclude: Tacrolimus conversion for rescue therapy after renal transplantation is efficient and safe with target trough levels between 5 -8 ng/ml. Frequent drug monitoring is necessary, especially within the first month after conversion. Previous cyclosporine dose can be used as a guideline for starting dose.
他克莫司是一种强效的新型免疫抑制药物,于1990年被用于25例肾移植受者的挽救治疗,这些患者存在持续性排斥反应(n = 24)或严重的环孢素毒性(n = 1)。在转换为他克莫司治疗前,血清肌酐从138±14(转换前3个月)显著升高(p < 0.001)至295±26μmol/l。他克莫司挽救治疗在移植后73±9个月开始,随访时间为8±1个月。对结果、药代动力学和副作用进行了分析。接受他克莫司治疗的患者生存率为100%。3个月时移植物存活率为88%,8个月时为70%。在观察期内血清肌酐保持稳定(8个月后肌酐:271±26μmol/l)。初始剂量为9.6±0.3mg/天(0.14±0.01mg/kg/天),1个月后他克莫司剂量可降至6.0±0.9mg/天(0.09±0.02mg/kg/天;p < 0.001)。他克莫司谷浓度调整至5 - 8ng/ml的治疗窗。每位患者平均需要进行3.4±0.5次剂量调整,主要在转换后的第一个月内(70%)。观察到个体间他克莫司剂量存在高度变异性。末次环孢素剂量是1个月后所需他克莫司剂量的良好预测指标(r = 0.88;p < 0.001)。总体而言,共记录到82例不良事件,其中29例(35%)与高谷浓度(> 10ng/ml)相关。相比之下,3例谷浓度< 4ng/ml的患者存在持续性排斥反应。血压和常规实验室数据保持不变。类固醇剂量可从12±2mg/天逐渐减至5±0.3mg/天(p < 0.02)。转换后牙龈增生和多毛症有所改善。我们得出结论:肾移植后转换为他克莫司进行挽救治疗是有效且安全的,目标谷浓度在5 - 8ng/ml之间。需要频繁进行药物监测,尤其是在转换后的第一个月内。先前的环孢素剂量可作为起始剂量的指导。